Researchers Identify 453 Malaria Peptides for Cross-Species Vaccine, With 2 Protecting Rodents
Updated
Updated · Nature.com · Jul 1
Researchers Identify 453 Malaria Peptides for Cross-Species Vaccine, With 2 Protecting Rodents
3 articles · Updated · Nature.com · Jul 1
Summary
A Nature study mapped 453 unique Plasmodium peptides from infected reticulocytes to 166 proteins, giving malaria vaccine developers a new set of validated CD8+ T-cell targets.
Seventy-five of those antigens were conserved housekeeping proteins expressed across multiple parasite life stages, supporting their potential use in a cross-stage, cross-species vaccine against P. vivax and P. falciparum.
Samples from both P. vivax- and P. falciparum-infected people recognized the newly identified epitopes, and identical peptides were presented across different HLA-A, HLA-B, HLA-C and HLA-E alleles.
Non-human primates showed blood and liver T-cell responses after infection or immunization with attenuated parasites, while two antigens triggered protective CD8+ T-cell-mediated immunity in rodent models.
The findings address a key bottleneck in malaria vaccine design—the shortage of validated T-cell epitope targets—at a time when existing vaccines have expanded options but still face efficacy limits.
Could targeting the malaria parasite's core machinery finally create a universal vaccine it cannot escape?
This breakthrough targets two malaria species. Will it finally close the vaccine gap for the neglected P. vivax strain?
Breakthrough Discovery of 453 Plasmodium Peptides Fuels Hope for Universal Malaria Vaccine by 2030
Overview
In late 2025 and early 2026, researchers made a major breakthrough by discovering 453 unique Plasmodium peptides using immunopeptidomic analysis. This method enabled the unbiased detection of Plasmodium antigens, which are presented on infected reticulocytes through HLA-I molecules. These peptides map to 166 different parasite proteins, with most being essential housekeeping proteins that are always present throughout the parasite’s life cycle. Importantly, many of these peptides were found in different individuals, suggesting they could be used to develop a universal malaria vaccine that targets the parasite at multiple stages and works broadly across populations.